AllianceBernstein’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

AllianceBernstein’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-49,230	Closed	-$72K	–	3081
2016 Q1	$72K	Sell	49,230 -12,600	-20%	-$24.9K	﹤0.01%	2854
2015 Q4	$198K	Sell	61,830 -200	-0.3%	-$962	﹤0.01%	2750
2015 Q3	$388K	Buy	62,030 +2,730	+5%	+$25.5K	﹤0.01%	2577
2015 Q2	$589K	Buy	59,300 +15,400	+35%	+$135K	﹤0.01%	2534
2015 Q1	$324K	Buy	43,900 +9,300	+27%	+$62.6K	﹤0.01%	2649
2014 Q4	$185K	Hold	34,600	–	–	﹤0.01%	2826
2014 Q3	$174K	Hold	34,600	–	–	﹤0.01%	2815
2014 Q2	$232K	Buy	34,600 +33,958	+5,289%	+$216K	﹤0.01%	2772
2014 Q1	$5K	Buy	642 +291	+83%	+$1.73K	﹤0.01%	3345
2013 Q4	$1K	Hold	351	–	–	﹤0.01%	3436
2013 Q3	$1K	Buy	+351	New	+$1.22K	﹤0.01%	3450

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AllianceBernstein's NWBO Position: Q2 2016 in Review

AllianceBernstein sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 49,230 shares — an estimated $72K sold.

AllianceBernstein first reported a position in NWBO in Q3 2013 and held it in 11 quarters. The position peaked at $589K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

AllianceBernstein reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
AllianceBernstein sold 49,230 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $72K.
AllianceBernstein first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2013 and held it in 11 quarters.
AllianceBernstein's Northwest Biotherapeutics, Inc. Common stock position peaked at $589K in Q2 2015.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on AllianceBernstein's 13F filing for Q2 2016, filed 11 Aug 2016.